News

Here you can find the latest TOPADUR news & events.

19.5.2022

Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

7.4.2022

Press Release

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

23.3.2022

Press Release

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

15.10.2021

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

5.10.2021

Press Release

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

6.7.2021

Press Release

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.